The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support ...

US FDA accepts for review Milestone Pharma’s response to CRL for Cardamyst nasal spray: Montreal Monday, July 14, 2025, 11:00 Hrs [IST] Milestone Pharmaceuticals Inc., a biophar ...

New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® ...

A nasal spray called FluMist has been approved by the U.S. Food and Drug Administration as an alternative to the traditional injection of the flu vaccine. Krista McNally Sep 24, 2024, 9:30 PM ...

Half of the subjects were given the esketamine nasal spray in one of two strengths, along with a new oral antidepressant that varied from person to person. The other group was given a new oral ...

Children who have an allergy that could cause anaphylaxis symptoms such throat swelling and other severe reactions have long had to carry an epinephrine injectable pen with them or have one stored ...

Today’s health headlines: ketamine nasal sprays offer a new option for people with treatment-resistant depression. Plus, how ...

FluMist is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a ...